FDA Approves Mavyret to Treat All Major Hepatitis C Genotypes

Today, the FDA approved Mavyret (glecaprevir/pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis, including patients with moderate-to-severe kidney disease and those on dialysis.
Mavyret is also approved for adults with HCV genotype 1 previously treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor, according to a press release.
“This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients with genotype 1 infection, the most common HCV genotype in the United States, who were not successfully treated with other direct-acting antiviral treatments in the past,” Edward Cox, MD, director of Antimicrobial Products at the FDA Center for Drug Evaluation and Research, said in the release.
The approval was based on safety and efficacy data from clinical trials of approximately 2300 adults with genotypes 1-6 HCV infection without cirrhosis or with mild cirrhosis.
The results of the study showed 92% to 100% of patients who received Mavyret for an 8, 12, or 16-week duration had no virus detected in the blood 12 weeks after treatment ended. Treatment duration differs depending on a patient’s treatment history, viral genotype, and cirrhosis status, according to the release.
The most common adverse events were headache, fatigue, and nausea.
Mavyret is the first 8-week treatment regimen approved for all HCV genotypes 1-6 in treatment-naïve adults without cirrhosis, according to the release. Standard treatment length was previously 12 weeks or more. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.